D.A. Davidson & CO. Boosts Stock Position in Pfizer Inc. $PFE

D.A. Davidson & CO. boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 58.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,068,515 shares of the biopharmaceutical company’s stock after buying an additional 1,130,014 shares during the period. D.A. Davidson & CO.’s holdings in Pfizer were worth $74,381,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the stock. Brighton Jones LLC grew its holdings in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC raised its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Pfizer by 69.0% during the first quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company’s stock valued at $1,600,000 after purchasing an additional 25,785 shares in the last quarter. Flagship Harbor Advisors LLC boosted its position in shares of Pfizer by 2.4% during the first quarter. Flagship Harbor Advisors LLC now owns 66,400 shares of the biopharmaceutical company’s stock valued at $1,683,000 after buying an additional 1,585 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. increased its holdings in Pfizer by 11.1% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 323,471 shares of the biopharmaceutical company’s stock worth $8,197,000 after buying an additional 32,203 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

PFE has been the topic of several research analyst reports. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Finally, Morgan Stanley cut their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.13.

Pfizer Stock Performance

Shares of PFE opened at $24.84 on Wednesday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.17. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock has a market cap of $141.23 billion, a price-to-earnings ratio of 13.21, a PEG ratio of 0.82 and a beta of 0.55. The business has a 50-day simple moving average of $24.89 and a two-hundred day simple moving average of $24.13.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the company posted $0.60 EPS. The firm’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.